Fig. 2.
Overall survival in: (A) All patients; (B) BEV–PAC subpopulation; and (C) BEV–CAP subpopulation. BEV–CAP, bevacizumab plus capecitabine; BEV–PAC, bevacizumab plus paclitaxel; CI, confidence interval.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.